Pharmaceutical developer Biogen (BIIB) is making substantial progress in its research, which is driving a gradual rise in its share price. However, will the company be able to survive despite a continued decline in its financials? Read more to find out.Pharmaceutical company Biogen Inc. (NASDAQ:) is one the leading companies in the biopharma space, with a market capitalization of $40.77 billion. The stock has gained 11.6% year-to-date, following its 19.5% decline over the past year.
BIIB has been gaining momentum owing to its breakthrough research in multiple spheres. However, the company’s bleak growth outlook is a cause for concern.
Click here to checkout our Healthcare Sector Report for 2021
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.